Valuation: Viyash Scientific Limited

Capitalization 88.18B 960M 830M 752M 722M 1.32B 1.37B 8.9B 3.55B 42.25B 3.6B 3.53B 151B P/E ratio 2024
-79.9x
P/E ratio 2025 154x
Enterprise value 92.36B 1.01B 870M 788M 756M 1.38B 1.44B 9.32B 3.72B 44.25B 3.77B 3.69B 159B EV / Sales 2024
2.4x
EV / Sales 2025 2.38x
Free-Float
47.13%
Yield 2024 *
-
Yield 2025 -
1 day+0.37%
1 week-7.89%
Current month-4.98%
1 month-6.78%
3 months-2.70%
6 months+13.96%
Current year-2.93%
1 week 194.95
Extreme 194.95
223.95
1 month 194.95
Extreme 194.95
239.05
Current year 188.2
Extreme 188.2
239.05
1 year 111
Extreme 111
260.3
3 years 61.8
Extreme 61.8
260.3
5 years 61.8
Extreme 61.8
336.4
10 years 42.45
Extreme 42.45
336.4
Manager TitleAgeSince
Chief Executive Officer 62 2025-12-15
Compliance Officer - 2024-12-16
Chief Administrative Officer - 2013-12-31
Director TitleAgeSince
Chairman 78 -
Director/Board Member 66 2020-08-24
Director/Board Member 65 2020-11-05
Change 5d. change 1-year change 3-years change Capi.($)
+0.37%-7.89%+37.78%+223.33% 953M
-3.30%-4.90%+4.54%+204.72% 897B
-3.60%-2.68%+43.50%+52.32% 591B
-2.89%+2.03%+8.37%+47.64% 418B
-2.03%-3.33%+15.93%+29.85% 368B
-2.08%-2.22%+22.48%+37.53% 313B
-2.24%-2.56%+24.82%+57.56% 312B
-3.92%-3.03%+24.13%+4.12% 297B
-4.23%-3.56%+15.56%+55.60% 204B
-2.69%+0.13%+24.70%+77.48% 184B
Average -2.65%-1.40%+22.18%+79.02% 358.47B
Weighted average by Cap. -3.02%-0.80%+19.21%+84.28%

Financials

2024 2025
Net sales 13.7B 149M 129M 117M 112M 205M 214M 1.38B 552M 6.56B 560M 548M 23.53B 15.51B 169M 146M 132M 127M 232M 242M 1.57B 625M 7.43B 634M 620M 26.65B
Net income -359M -3.91M -3.38M -3.06M -2.94M -5.36M -5.59M -36.19M -14.46M -172M -14.66M -14.35M -616M 219M 2.38M 2.06M 1.87M 1.79M 3.27M 3.41M 22.07M 8.82M 105M 8.94M 8.75M 376M
Net Debt 4.2B 45.76M 39.58M 35.84M 34.41M 62.75M 65.52M 424M 169M 2.01B 172M 168M 7.22B 4.18B 45.53M 39.38M 35.66M 34.23M 62.44M 65.19M 422M 169M 2B 171M 167M 7.18B
Logo Viyash Scientific Limited
SeQuent Scientific Limited is an India-based animal health company. The Company provides a wide range of animal health products, including finished dose formulations, active pharmaceutical ingredients (APIs), as well as analytical services. The Company operates through the pharmaceuticals segment. The Company is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It is specialized in analytical and bio analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It provides analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer developed methods or in-house method development. The Company’s subsidiaries include Alivira Animal Health Limited and SeQuent Research Limited.
Employees
1,244
Date Price Change Volume
26-03-05 202.05 +0.37% 10,641
26-03-04 201.30 +0.60% 47,579
26-03-02 200.10 -5.90% 46,471
26-02-27 212.65 -3.34% 30,926
26-02-26 220.00 +0.30% 216,675
  1. Stock Market
  2. Equities
  3. VIYASH Stock